Geninus Presents Research Abstracts on Cancer Vaccines at ASCO

[Asia Economy Reporter Chunhee Lee] Geninus announced on the 29th that three research abstracts, including initial study results of single-cell-based patient-customized cancer vaccines and the development results of liquid biopsy-based early diagnosis technology for colorectal cancer, have been accepted at the American Society of Clinical Oncology (ASCO) and are scheduled to be presented in June.

ASCO is one of the world's top three cancer societies. It is an international academic event attended by more than 40,000 cancer specialists and global pharmaceutical company representatives from over 70 countries every year, where numerous clinical results of new cancer drugs are announced. It will be held in person from June 3 to 7.

At this ASCO, Geninus will present initial research results of cancer vaccines based on single-cell technology. They confirmed that neoantigens manufactured by sequencing cancer tissues from solid tumor patients and predicting T cell responses, and that neoantigens binding to T cells induce better cancer immune responses. Detailed abstract content will be disclosed next month.

They will also present results on the development of early cancer diagnosis technology through liquid biopsy. Using the DNA methylation pattern of cfDNA (cell-free DNA) circulating in the blood as a marker, they demonstrated excellent sensitivity and specificity in colorectal cancer patients. DNA obtained from the blood of colorectal cancer patients was analyzed using NGS technology to derive clinically meaningful results. This related content will also be disclosed next month.

Additionally, joint research results with AI software development company AM Square, which maximized NGS detection performance, will be presented. This research result was selected for the poster session.

This content was produced with the assistance of AI translation services.